Radioactivity level in relation to geological substrate: dynamics of natural and artificial radionuclides on Teucrium montanum L. (Lamiaceae) habitats.

There are no results of comparative ecological studies of the radionuclide activity concentration in the plants and soil in relation to geological substrate. Presented research encompasses the comparative analysis of the concentration of four radionuclides, three natural (40K, 226Ra, 232Th) and one artificial (137Cs) in soil samples and aerial plant parts of Teucrium montanum from different natural habitats on serpentinite and calcareous geological substrate. The activity concentrations of radionuclides were measured with high purity germanium (HPGe) detector and expressed as Bq kg-1. The calculated activity concentrations of 40K, 226Ra, 232Th, and 137Cs in soil samples from serpentinite/calcareous habitats are in range 39.6-91.0/59.3-1018.8, 1.7-5.5/4.3-52.4, 2.4-10.9/5.9-72.9, and 57.2-844.9/29.6-701.5 Bq kg-1, respectively. The activity concentrations of 40K, 226Ra, 232Th, and 137Cs in plant samples are in range 152.9-445.9/228.0-521.4, n.d.-1.2/0.6-5.6, n.d./0.2-0.9, and 1.0-46.4/1.7-7.0 Bq kg-1, respectively. The obtained results showed that the quantities of 137Cs are greater in the soil and plant material from the serpentinite habitats, while quantities of 40K, 226Ra, and 232Th are greater in the soil and plant material from calcareous habitats. In general, the level of radioactivity in plants and soil depends on the type of the geological substrate. The content of radionuclides in plants is correlated with the radionuclide content in the soil. In addition to other specifics in physical and chemical properties, serpentinite habitats are characterized by an increased amount of Cs in the soil, which causes an increased amount of this radionuclide in plants such as Teucrium montanum.

A five-compartment biokinetic model for 90 Y-DOTATOC therapy.

PURPOSE: Neuroendocrine tumors (NETs) are now routinely treated by radiopeptide targeted therapy using somatostatin receptor-binding peptides such as 90 Y- and 177 Lu-DOTATOC. The objective of this work was to develop a biokinetics model of 90 Y labelled DOTATOC, which is applied in the therapy of NETs to estimate doses in kidney and tumor. METHODS: A multi-compartment model described by two sets of differential equations, one set for the actual 30-min infusion and the other set for the post-infusion period was developed and activities were measured by liquid scintillation counting in blood (compartment 1) and the urine (compartment 3). The inter-compartment transfer coefficients, λij , were varied to yield the best fit of the calculated to the measured time-activity data and the 90 Y-DOTATOC time-activity data in the five-compartments comprising the human body were thus determined. The resulting time-activity curves were integrated over the interval from 0 to 72 h post administration to obtain the number of radioactive decays in each compartment and, in case of the kidneys and tumor, then multiplied by the self-dose 90 Y beta particle absorbed fraction, determined by Monte Carlo (MC) simulation, the kidney and tumor absorbed doses. RESULTS: Transfer coefficients λij , were determined for five-compartments for all patients. Time- activity curves of 90 Y-DOTATOC in 14 patients were determined, and two typical ones are shown graphically. Absorbed doses in the tumor and kidneys, obtained by the developed method, were determined. The mean absorbed dose in a kidney per unit of administered activity is 1.43 mGy/MBq (range 0.73-2.42 mGy/MBq). The tumor dose was determined as 30.94 mGy/MBq (range 20.05-42.31 mGy/MBq). CONCLUSION: Analytical solution of a biokinetic model for 90 Y-DOTATOC therapy enabled determination of the transfer coefficients and derivation of time-activity curves and kidney and tumor absorbed doses for 14 treated patients. The model can be applied to other radionuclides where elimination is predominantly through urine, which is often the case in radiopharmaceuticals.